Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.55 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.55 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.55 |
| ▸ | DRD1 | P21728 | 15/20 | 0.67 |
| ▸ | DRD2 | P14416 | 11/20 | 0.67 |
| ▸ | F3 | P13726 | 7/20 | 0.67 |
| ▸ | DRD3 | P35462 | 7/20 | 0.67 |
| ▸ | DRD5 | P21918 | 5/20 | 0.67 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | HTR1A | P08908 | 1/20 | 0.61 |
| ▸ | DRD4 | P21917 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL29999956 | 1.00 | DRD1 (0.67) | DRD1DRD2F3DRD3DRD5 | |
| SCHEMBL910355 | 0.97 | DRD1 (0.70) | DRD1DRD2F3DRD3DRD5 | |
| SCHEMBL29999932 | 0.97 | DRD1 (0.70) | DRD1DRD2F3DRD3DRD5 | |
| Hydrochloric Acid SCHEMBL30000488 | 0.96 | LMNA (0.71) | DRD1DRD2F3DRD3DRD5 | |
| Hydrochloric Acid SCHEMBL910111 | 0.96 | LMNA (0.71) | DRD1DRD2F3DRD3DRD5 | |
| Phosphoric Acid SCHEMBL29999988 | 0.95 | DRD1 (0.64) | DRD1DRD2F3DRD3DRD5 | |
| Phosphoric Acid SCHEMBL910139 | 0.95 | DRD1 (0.64) | DRD1DRD2F3DRD3DRD5 | |
| Lactic Acid SCHEMBL29999769 | 0.92 | DRD1 (0.61) | DRD1DRD2F3DRD3DRD5 | |
| Lactic Acid SCHEMBL910623 | 0.92 | DRD1 (0.61) | DRD1DRD2F3DRD3DRD5 | |
| Cadaverine Tartrate SCHEMBL910404 | 0.92 | DRD1 (0.61) | DRD1DRD2F3DRD3DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220387403-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY | CVI PHARMACEUTICALS LIMITED (KY) | 2022-12-08 | — | — | US | disclosed |
| EP-2370434-B1 | ISOQUINOLINYL-CONTAINING ALKALOID COMPOUNDS AND COMPOSITIONS USEFUL FOR REDUCING LIPID LEVELS | CVI PHARMACEUTICALS LTD (KY) | 2014-09-17 | — | — | EP | disclosed |
| US-20110009628-A1 | Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same | CVI PHARMACEUTICALS LIMITED (KY) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009628-A1 | Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same | LIPC, LDLR, PCSK9 | ADRA1D 2553/4885ADRA1A 1933/4885ADRA1B 2003/4885 |
| US-20220387403-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY | LIPC, FABP1, CPT1A | ADRA1D 2367/4885ADRA1A 1340/4885ADRA1B 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.